Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SIGILON THERAPEUTICS, INC.

(SGTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sigilon Therapeutics : to Participate in Two Upcoming Healthcare Investor Conferences

09/02/2021 | 07:01am EDT

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in two upcoming healthcare investor conferences.

Presentation Details:

Event: Morgan Stanley 19th Annual Global Healthcare Conference
Date:
Friday, September 10, 2021
Time: 8:00 AM ET
Details:
Live Fireside Chat

Event: H.C. Wainwright 23rd Annual Global Investment Conference
Date: Monday, September 13, 2021
Time: 7:00 AM ET
Details:
On Demand Corporate Presentation

Webcasts of the Morgan Stanley fireside chat and the H.C. Wainwright corporate presentation will be accessible under “Events and Presentations” in the Investors & Media page of the Company's website at www.sigilon.com. A replay of each webcast will be available at the same location following the event.

About Sigilon Therapeutics
Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates are non-viral engineered cell-based therapies designed to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, lysosomal diseases and diabetes. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

Investor Contact
Robert Windsor, Jr., J.D.
VP, Head of Investor Relations
Sigilon Therapeutics
robert.windsor@sigilon.com
617-586-3837

Media Contacts
Amy Bonanno
Solebury Trout
abonanno@soleburytrout.com
914-450-0349

Brandon Hagen
Manager, Communications
Sigilon Therapeutics
brandon.hagen@sigilon.com
617-586-2851


Primary Logo

Source: Sigilon Therapeutics, Inc.

2021 GlobeNewswire, Inc., source Press Releases

All news about SIGILON THERAPEUTICS, INC.
09/09SIGILON THERAPEUTICS : UK Regulator Accepts Sigilon's Clinical Trial Application for Lysos..
MT
09/09Sigilon Therapeutics Announces Acceptance of Clinical Trial Application in the UK for S..
GL
09/09Sigilon Therapeutics, Inc. Announces Acceptance of Clinical Trial Application in the UK..
CI
09/02SIGILON THERAPEUTICS : to Participate in Two Upcoming Healthcare Investor Conferences
AQ
08/10SIGILON THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Res..
AQ
08/10SIGILON THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Business Highligh..
PU
08/10SIGILON THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD ..
AQ
08/10SIGILON THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Business Highligh..
AQ
08/10Sigilon Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Se..
CI
08/10Sigilon Therapeutics, Inc. Announces Resignation of Deya Corzo as Chief Medical Officer
CI
More news
Analyst Recommendations on SIGILON THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 11,7 M - -
Net income 2021 -78,0 M - -
Net cash 2021 117 M - -
P/E ratio 2021 -2,23x
Yield 2021 -
Capitalization 178 M 178 M -
EV / Sales 2021 5,20x
EV / Sales 2022 -3,91x
Nbr of Employees 99
Free-Float 78,1%
Chart SIGILON THERAPEUTICS, INC.
Duration : Period :
Sigilon Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SIGILON THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 5,54 $
Average target price 20,75 $
Spread / Average Target 275%
EPS Revisions
Managers and Directors
RogÚrio Vivaldi Coelho President, Chief Executive Officer & Director
Josias Pontes Vice President & Head-Finance
Douglas G. Cole Chairman
Deya Corzo Chief Medical Officer
Martha Rook Chief Technical Operations Officer
Sector and Competitors
1st jan.Capi. (M$)
SIGILON THERAPEUTICS, INC.-88.47%178
MODERNA, INC.226.29%137 595
LONZA GROUP AG32.74%61 065
IQVIA HOLDINGS INC.41.93%48 579
SEAGEN INC.-0.30%31 768
CELLTRION, INC.-39.00%25 528